Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: Late is Better Than Not Done at All by Hendrawati, Hendrawati et al.
Percutaneous Coronary Intervention in ST-Segment 
Elevation Myocardial Infarction: Late is Better Than Not 
Done at All
1
Hendrawati Hendrawati1,2*, Mohammad Saifur Rohman2,3, Cholid Tri Tjahjono3, Sasmojo Widito3, 
Budi satrijo3, Yoga Waranugraha3, Muhammad Rizki Fadlan2, Iskandar Iskandar2
Department of Cardiology and Vascular Medicine, Dr. Haryoto General Hospital, Lumajang, Indonesia.
Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
2
A R T I C L E I N F O A B S T R A C T
1. Introduction
*Corresponding author at: Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine,
Universitas Brawijaya, Malang, Indonesia
E-mail address: hendrawati.dr@gmail.com (Hendrawati).
Heart Science Journal
Contents list available at www.heartscience.ub.ac.id
Heart Sci J 2020; 1(3): 21-26
Journal Homepage : www.heartscience.ub.ac.id
Background : For ST-segment elevation myocardial infarction (STEMI) patients, reperfusion through primary 
percutaneous coronary intervention (PCI) must be done to return the coronary arteries' blood flow. However, a 
large proportion of patients received late PCI. This study aimed to assess the impact of late PCI on the clinical 
outcomes of STEMI patients. 
Methods : A retrospective cohort study was conducted in Saiful Anwar General Hospital from January 2017 to 
April 2018. A total of 192 STEMI patients were divided into three groups: (1) on-time PCI; (2) late PCI; and (3) 
no PCI. The outcome measured included six months and 12 months of cardiovascular mortality and hospital 
readmission because of worsening heart failure and recurrent myocardial infarction (MI).
Results: At six-month follow-up period, we found that hospital readmission was higher in the no PCI group (9.2% 
vs. 12.1% vs. 34.8%; p = 0.009). The recurrent MI (0% vs. 0% vs. 7.2%; p = 0.010) and worsening heart failure 
(6.2% vs. 8.6% vs. 33.3%; p < 0.001) was also higher in the no PCI group. On 12 months follow up period, the 
mortality (4.6% vs. 13.8% vs. 21.7%; p = 0.015) and hospital readmission (15.4% vs. 20.7% vs. 42%; p = 0.001) 
rate was higher in no PCI group. Hospital readmission because of worsening heart failure was also higher in no 
PCI group (9.2% vs. 17.2% vs. 37.7%; p = 0.015). 
Conclusion: Not performing revascularization was correlated with higher mortality and hospital readmission rate 
in STEMI patients. Late PCI was associated with better outcomes than not conducting revascularization. 
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 STEMI is the most severe manifestation of the acute coronary 
syndrome (ACS). Generally, STEMI is caused by the rupture of athero-
matous plaque, leading to thrombus generation, resulting in acute total 
occlusion of the coronary artery.1 Following interrupted coronary blood 
flow, myocardial damage begins. The more prolonged ischemia 
occurred, the greater the amount of myocardial damage. Revasculariza-
tion using primary PCI conducted within 12 hours following onset is 
the best treatment strategy in STEMI patients.2,3 Several studies empha-
sized the strong correlation between the delay in revascularization and 
mortality in STEMI patients accompanied with out-of-hospital cardiac 
arrest (OHCA) or cardiogenic shock.4-6 In STEMI accompanied by 
cardiogenic shock without OHCA, between 60-180 minutes from the 
first medical contact, every 10 minutes of treatment delay will produce  
3.3 additional deaths per 100 patients treated with PCI.7 
 Previous studies also have shown that STEMI patients 
received more benefit by primary PCI conducted less than 12 hours 
from the onset of STEMI symptoms.8 However, for STEMI patients with 
onset of more than 12 hours, the evidence to support performing PCI is 
not strong enough. Occluded Artery Trial (OAT) revealed no benefit of 
late reperfusion for patients who arrive over three days after the 
onset.9,10 However, several studies showed that conducting PCI is still 
beneficial for myocardial saving, even though it was done late.11,12 This 
study aimed to assess the impact of late PCI on the clinical outcomes of 
STEMI patients.
2. Methods
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2.1. Study Design 
 It was a retrospective cohort study. We used a consecutive 
sampling method. This study protocol was recognized and approved 
by the ethical committee of Saiful Anwar General Hospital.
2.2. Study population
 AAll patients admitted to Saiful Anwar General Hospital, 
Malang, Indonesia, with confirmed STEMI from January 2017 to April 
2018, according to the 2017 ESC Guideline for STEMI, were included 
in this study. We excluded patients with: (1) congenital heart disease; 
(2) valvular heart disease; (3) pulmonary hypertension; (4) idiopathic 
cardiomyopathy; (5) severe liver or renal dysfunction; (6) malignancy, 
(7) autoimmune disease; or (8) uncontrolled systemic diseases 
(Figure1).
2.3. Baseline Data Collection 
 All information about the patient, including demographic 
data, payment status, Killip class, and risk stratification using Throm-
bolysis in Myocardial Infarction (TIMI) risk score and Global Registry of 
Acute Coronary Events (GRACE) score were collected using a standard 
case-report form. The TIMI score is classified into two categories, the 
score <5 is classified as low risk, while the score> 5 is high risk.13 We 
used the GRACE score to estimate mortality within six months in STEMI 
patients. The GRACE score is classified into three groups: (1) GRACE 
score of <109 (low risk); (2) GRACE score 109 to 140 (moderate risk); 
and (3) GRACE score of >140 (high risk).2,14,15 
Figure 1. Study flowchart
2.4. Exposure and Outcome
 The exposure was the reperfusion strategy. STEMI Patients 
were divided into three separate groups based on the reperfusion 
strategy: on-time PCI group, late PCI group, and no PCI group. On-time 
PCI was defined as PCI that was performed within the time frames 
according to the 2017 ESC Guidelines for STEMI management. PCI that 
performed beyond the time frames determined by the 2017 ESC Guide-
lines for STEMI management was Late PCI.2 The late PCI criteria 
included PCI performed beyond 12 hours from the onset of chest pain 
symptoms in STEMI patients with stable hemodynamic or rescue PCI in 
>90 minutes after failed fibrinolytic therapy. STEMI patients who 
received optimal medical treatment but did not receive any reperfusion 
or failed to undergo PCI (due to abnormal anatomical morphology of 
coronary artery, passed away before PCI, and refused PCI because of 
financial problems or not covered by insurance) were classified as no 
PCI.
 The outcome measured was six months and 12 months of 
mortality and hospital readmission. Readmission data were obtained 
from medical records or interview questionnaires on phone calls about 
hospital readmission after discharge due to recurrent MI and worsening 
heart failure. Mortality data were obtained from family member 
information declared dead from phone call interviews or medical 
records that showed mortality during hospitalization. The study 
flowchart is summarized in Figure 1.
2.5. Statistical analysis
 IBM SPSS version 22 software was used to conduct statistical 
analysis. Number and percentages were used to show categorical data. 
Mean and standard deviation were used to present numeric data. 
Statistical analysis for numeric data with normal distribution was 
performed using the analysis of variance (ANOVA). However, if the 
data abnormally distributed, the Kruskal Wallis test was used to 
conduct statistical analysis of numerical data. Statistical analysis for 
categorical data was conducted using the Chi-square test. A p-value of 
<0.005 is considered significant statistically.
3. Results
3.1. Patients basic characteristics
 We collected the data from 256 STEMI patients. However, 
about 64 STEMI patients were excluded because of incomplete data, 
lost follow-up, and refused participation. Finally, a total of 192 patients 
were involved in the analysis process. The patients' mean age was 57.7 
± 10.2 years, and 81.3% of them were male. The one-year readmission 
and mortality rates were 26.6% and 13.5%, respectively. The most 
common cause of readmission is worsening heart failure (62%). Table 
1 is summarizing patients' baseline characteristics.
 Among the three groups of patients, from baseline character-
istics, no significant differences in the proportion of age, sex, chest pain 
onset, TIMI risk score, GRACE score, Killip class, and medication 
adherence, except payment status, were found. Coronary angiographic 
characteristics data in groups of STEMI patients receiving PCI treatment 
were not significantly different in terms of the number of coronary 
lesions, the infarct-related artery (IRA), and TIMI flow. A total of 123 
(64%) patients were treated by PCI, while 69 (36%) received only 
optimal medical therapy.
3.1. Clinical outcome
 During the six-month follow-up period, we found that 
hospital readmission was higher in the no PCI group (9.2% vs 12.1% vs 
34.8%; p = 0.009). We also conducted a subgroup analysis of the cause 
of hospital readmission. Higher percentage of recurrent MI was found 
in the no PCI group (0% vs. 0% vs. 7.2%; p = 0.010). A higher percent-
age of worsening heart failure was also found in the no PCI group (6.2% 
vs 8.6% vs 33.3%; p < 0.001). The mortality rate among the three 
groups was not significantly different (3.1% vs 5.2% vs 10.1%; p = 
0.221). 
 During the follow-up period of 30 days following hospital 
discharge, three patients in suboptimal dose of ACEI group were passed 
away. Two patients passed away because of cardiogenic shock, while 
one patient passed away because of sudden cardiac death. Data analysis
 During the 12 months follow up period, the mortality (4.6% 
vs. 13.8% vs. 21.7%; p = 0.015). and hospital readmission (15.4% vs. 
20.7% vs. 42%; p = 0.001)  rate was higher in no PCI group
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From subgroup analysis, we found that worsening heart failure causing 
hospital readmission was higher in no PCI group (9.2% vs 17.2% vs 
37.7%; p = 0.015). However, recurrent MI among the three groups 
(4.6% vs 1.7% vs 7.2%; p = 0.340) was not significantly different. The 
clinical outcomes were summarized in table 2. Kaplan-Meier curve 
showing survival from hospital readmission and mortality during 12 
months follow-up period is shown in figure 2. 
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Figure 2. Kaplan-Maier curves for hospital readmission (B) and mortality (B)
Table 1. Baseline charaterictic of the patients
Variables On-time PCI(n=65)
No PCI
(n=69) p
 
56 + 10.4
52 (80.0)
13(20.0)
64 (98.5)
1 (1.5)
44 (67.7)
21 (32.2)
55 (84.6)
10 (15.4)
31 (47.7)
20 (30.8)
14 (21.5)
Age
Sex
Male
Female
Payment status
Insurance
Regular
Symptom onset
<12 hours
>12 hours
TIMI score
<5
>5
GRACE score
Low
Intermediate
High
59 + 11.17
54 (78.3)
15 (21.7)
41 (59.4)
28 (40.6)
40 (58.0)
29 (42.0)
51 (73.9)
18 (26.1)
28 (40.6)
17 (24.6)
24 (34.8)
0.450
0.336
0.000
0.930
0.389
0.518
57 + 8.9
51 (87.9)
7 (12.1)
50 (86.2)
8 (13.8)
28 (48.3)
30 (51.7)
44 (24.1)
14 (24.1)
23 (39.7)
18 (31.0)
17 (29.3)
Late PCI
(n=58)
Group
48 (73.8)
2 (3.1)
0 (0.0)
15 (23.1)
51(82.3)
0 (0.0)
28 (43.1)
4 (6.2)
33 (50.8)
8 (12.3)
14 (21.5)
43 (66.2)
1 (1.5)
13 (20.0)
51 (78.5)
Killip
I
II
III
IV
Medication adherence
Infarct related artery
Left main
Left anterior descending artery
Left circumflex artery
Right coronary artery
Number of lesions
1
2
3
TIMI flow
0-1
2
3
48 (69.6)
3 (4.3)
1(1.4)
17 (24.6)
61 (89.7)
-
-
-
-
-
-
-
-
-
-
0.556
0.080
0.155
0.520
0.203
40 (69.0)
5 (8.6)
2 (3.4)
11 (19.0)
55 (94.8)
0 (0.0)
35 (60.3)
3 (5.2)
20 (34.5)
7 (12.5)
17 (30.4)
32 (57.1)
3 (5.2)
9 (15.5)
46 (79.3)
Note, data were presented in mean ± SD or n(%); GRACE = Global Registry of Acute Coronary Events; PCI = percutaneous coronary intervention; TIMI = Thrombol-
ysis in Myocardial Infarction
Table 2. Outcomes
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Variables On-time PCI(n=65)
No PCI
(n=69) p
 
56 + 10.4
52 (80.0)
13(20.0)
64 (98.5)
1 (1.5)
44 (67.7)
21 (32.2)
6 months of follow up
Mortality
Readmission
Cause of readmission
Recurrent myocardial infarction 
Heart failure
Angina
12 months of follow up
Mortality
Readmission
Cause of readmission
59 + 11.17
54 (78.3)
15 (21.7)
41 (59.4)
28 (40.6)
40 (58.0)
29 (42.0)
0.450
0.336
0.000
0.930
0.389
57 + 8.9
51 (87.9)
7 (12.1)
50 (86.2)
8 (13.8)
28 (48.3)
30 (51.7)
Late PCI
(n=58)
Group
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4. Discussion
 The hospital readmission rate for six months and twelve 
months follow-up was higher in no PCI group. From the subgroup 
analysis, there were essential variations causes of hospital admission. 
Recurrent MI contributed to hospital readmission for six months 
follow-up period. However, worsening heart failure contributed to 
hospital readmission for six months and twelve months follow-up 
period. From the subgroup analysis, it was found that the most common 
reason behind hospital readmission was the worsening of heart failure. 
It was significantly different between the on-time PCI and no PCI 
groups (p < 0.001) and between the late PCI and no PCI groups (p = 
0.019).
 The meta-analysis study by Yang et al., which involved 11 
studies reported the incidence of readmission related to myocardial 
infarction, showed significantly different results (p = 0.008). There was 
a tendency of decreasing rates of recurrent MI in late revascularization 
groups in all patients. Subgroup analysis showing late reperfusion 
beyond 12 hours was associated with a significant reduction of the 
incidence of recurrent MI compared to groups with optimal medical 
therapy (p <0.001), but this difference did not show significant results 
in 2-60 days late reperfusion (p = 0.55). Whereas for readmission 
related to worsening heart failure, the meta-analysis of Yang et al. 
reported that late reperfusion of beyond 12 hours was significantly 
correlated with a reduction in worsening heart failure (p = 0.004).16 
 According to the open artery hypothesis, time-dependent 
myocardial rescue (early) and a time-independent process (late) are 
involved in the extended paradigm of acute MI. Late coronary reperfu-
sion seems to disturb the adverse remodelling process of the heart, 
chamber enlargement, and systolic dysfunction. Late coronary reperfu-
sion seems to disturb the adverse remodelling process of the heart, 
chamber enlargement, and systolic dysfunction. In the late reperfusion 
setting through the contraction band necrosis, cellular oedema, and 
intramyocardial haemorrhage, favourable myocardial stiffening is also 
believed to take place more readily.17,18 Moreover, persistent occlusion 
of the IRA has been related to an increase in the rate of apoptosis in the 
peri-infarct region markers of ischemia. Left ventricular dilatation, 
progressive left ventricular systolic dysfunction through apoptosis, 
gradual cells lost are thought to have a role in the terrible ventricular 
remodelling.19,20 Patients with an open IRA significantly had lower 
30-day mortality than a not opened IRA (p <0.001). This advantage 
could not be explained by myocardial rescue alone, because it resided 
following adjustment for left ventricular ejection fraction (LVEF). The 
coronary artery's patency was also correlated with lower 30-day and 
1-year mortality, but not after adjustment for other late mortality 
variables. Having an open IRA at the first coronary angiography confers 
a survival benefit that expands beyond the advantages of myocardial 
rescue from thrombolytic treatment and is not related to LVEF.21 
 Beyond 12 hours Reperfusion AlternatiVe Evaluation 
(BRAVE-2) trial specifically included STEMI patients with the symptom 
onset ranging from 12 to 48 hours. They were randomized to conserva-
tive strategy and invasive strategy. A total of 365 STEMI patients were 
involved in the BRAVE-2 trial, revealed a statistically significant 
decrease in the size of the final infarction in the group receiving 
invasive strategy with single-photon emission computed tomography 
(SPECT) imaging at a median of 7.1 days. Clinical outcome results   
followed on days 30 and 90 did not show differences between both 
groups.12 Mortality rate was significantly lower in the invasive strategy 
group (11.1%) than the conservative group (18.9%), at four years 
follow up, reflecting the absolute risk difference of 7.8%.22
 Our study aimed to look for the impact of late PCI on the 
clinical outcome of STEMI patients without seeing the delay based on 
the division of time frames. Delay >72 hours are considered the same 
for the period after, while the data obtained for the delay in PCI in 
opening an IRA starts from 24 hours to 11 months. The research with 
better design might be warranted. The relatively small number of 
samples and the high exclusion rate of patients were also the drawbacks 
of this study besides the limited follow-up period of up to 12 months. 
Further research with a larger number of samples, a more extended 
follow-up period, and a more accurate analysis is needed.
5. Conclusion
 Not performing revascularization was correlated with higher 
mortality and hospital readmission rate in STEMI patients. Late PCI was 
associated with better outcomes than not conducting revascularization. 
However, conducting on-time PCI based on the guideline recommenda-
tion was the best approach for improving STEMI patients' outcomes.
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